| 1 |
35269424 | Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. | 2022 Feb 25 |
1 |
| 2 |
35312963 | Nectin-4: a Novel Therapeutic Target for Skin Cancers. | 2022 Apr |
1 |
| 3 |
35421529 | New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? | 2022 Jun |
1 |
| 4 |
35484425 | Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer. | 2022 Apr 28 |
1 |
| 5 |
33239713 | The biology and rationale of targeting nectin-4 in urothelial carcinoma. | 2021 Feb |
1 |
| 6 |
33692500 | Benefit of nectin-4 targeting with enfortumab vedotin confirmed. | 2021 Apr |
1 |
| 7 |
33747934 | Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. | 2021 |
1 |
| 8 |
33901032 | Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. | 2021 Sep 1 |
1 |
| 9 |
33943047 | Emerging agents for the treatment of metastatic urothelial cancer. | 2021 May |
1 |
| 10 |
33991512 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. | 2021 Jun |
1 |
| 11 |
34108177 | Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. | 2021 Sep 15 |
1 |
| 12 |
34281911 | NECTIN4 Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug Conjugate. | 2021 Sep 15 |
2 |
| 13 |
31823332 | Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma. | 2020 Jan |
1 |
| 14 |
32031899 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. | 2020 Apr 1 |
1 |
| 15 |
32406880 | Enfortumab vedotin to treat urothelial carcinoma. | 2020 May |
1 |
| 16 |
32552213 | The emerging role of antibody-drug conjugates in urothelial carcinoma. | 2020 Jul |
1 |
| 17 |
32668516 | Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. | 2020 Jul |
1 |
| 18 |
32751328 | Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. | 2020 Jul 29 |
1 |
| 19 |
32824340 | NECTIN4 Expression in Extramammary Paget's Disease: Implication of a New Therapeutic Target. | 2020 Aug 16 |
1 |
| 20 |
33019653 | Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors? | 2020 Oct 1 |
1 |
| 21 |
33604101 | Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin. | 2020 May-Jun |
1 |